Ipsen Adds Another Program Into Its Pre-Clinical R&D Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, METTL3
Retrieved on:
Monday, October 18, 2021
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, American Cancer Society, Risk, Methylation, Cell, Incidence, ADR, Blood, Cancer, Hematological Cancer Research Investment and Education Act, Senior, Heart, AML, Growth, Accent, RNA transfection, Protein, Therapy, RMP, METTL14, McNeil Consumer Healthcare, METTL3, RNA, Development, Neglected tropical disease research and development, Clinical trial, Patient, Biology, Data, Acute myeloid leukemia, Oncogene, Bone marrow, Apoptosis, SLAS Discovery, Patent, Aichi M6A, IPN, Pharmaceutical industry
Ipsen (Euronext: IPN; ADR: IPSEY) and Accent Therapeutics (Accent) have signed an exclusive worldwide-collaboration agreement to research, develop, manufacture, and commercialize Accents pre-clinical stage METTL3 program.
Key Points:
- Ipsen (Euronext: IPN; ADR: IPSEY) and Accent Therapeutics (Accent) have signed an exclusive worldwide-collaboration agreement to research, develop, manufacture, and commercialize Accents pre-clinical stage METTL3 program.
- Christelle Huguet, Senior Vice President, Head of Research, External Innovation and Early Development, Ipsen, said Oncology is a key focus area for Ipsen as we grow our pipeline.
- We are delighted to partner with Accent to progress the METTL3 program as we continue our expansion into hematologic oncology.
- Accent Therapeutics novel investigational small molecule inhibitors of METTL3 seek to treat specific sub-types of AML with high unmet medical need.